MARKET

IMMP

IMMP

Immutep
NASDAQ
1.690
+0.040
+2.42%
Opening 13:17 07/14 EDT
OPEN
1.650
PREV CLOSE
1.650
HIGH
1.700
LOW
1.650
VOLUME
39.44K
TURNOVER
--
52 WEEK HIGH
2.720
52 WEEK LOW
1.320
MARKET CAP
246.81M
P/E (TTM)
-8.2600
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IMMP last week (0707-0711)?
Weekly Report · 17h ago
Weekly Report: what happened at IMMP last week (0630-0704)?
Weekly Report · 07/07 10:09
Weekly Report: what happened at IMMP last week (0623-0627)?
Weekly Report · 06/30 10:12
Immutep Reports Promising Phase I Results for IMP761 in Autoimmune Diseases
TipRanks · 06/24 10:31
Immutep announces initial efficacy data from Phase I study of IMP761
TipRanks · 06/23 18:01
Immutep Announces Initial Efficacy Data And Continued Safety Data From Placebo-Controlled, Double-Blind First-In-Human Phase I Study Evaluating IMP761, LAG-3 Agonist Antibody For Autoimmune Diseases
Benzinga · 06/23 12:06
IMMUTEP ANNOUNCES POSITIVE UPDATE FROM PHASE I STUDY OF IMP761, A FIRST-IN-CLASS LAG-3 AGONIST ANTIBODY FOR AUTOIMMUNE DISEASES
Reuters · 06/23 12:00
Weekly Report: what happened at IMMP last week (0616-0620)?
Weekly Report · 06/23 10:09
More
About IMMP
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.

Webull offers Immutep Ltd - ADR stock information, including NASDAQ: IMMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMMP stock methods without spending real money on the virtual paper trading platform.